Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 20/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590558 | 0.94 | P2RY12 (0.82) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3937530 | 0.93 | P2RY12 (0.81) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4873260 | 0.92 | P2RY12 (0.85) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3327629 | 0.92 | P2RY12 (0.84) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4891753 | 0.91 | P2RY12 (0.82) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3325916 | 0.91 | P2RY12 (0.82) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3329645 | 0.90 | P2RY12 (0.81) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3324555 | 0.89 | P2RY12 (0.80) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4737239 | 0.89 | P2RY12 (0.80) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4740119 | 0.89 | P2RY12 (0.80) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |